Arvinas' reported profitability hinges on episodic collaboration milestones, with 2026Q2 revenue of $249.7M and operating income of $164.1M standing against a 2026Q3 revenue of just $0.5M and operating loss of $59.1M, which suggests the peak quarter may not reflect a sustainable run-rate.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | -$0.82+10.6% vs -$0.92 | $500,000-96.0% vs $12M |
Q3 2026 Aug 4, 2026 | $2.58+789.6% vs -$0.37 | $250M+311.3% vs $61M |
Q2 2026 May 12, 2026 | -$0.90+5.3% vs -$0.95 | $16M-6.1% vs $17M |
Q1 2026 Feb 24, 2026 | -$1.10-100.0% vs -$0.55 | $10M-74.5% vs $37M |
Arvinas (NASDAQ: ARVN) outlined upcoming clinical milestones across its oncology and neurology pipeline during its third-quarter 2026 earnings call, while reporting lower operating expenses and a cash runway projected into the second half of 2028. President and CEO Randy Teel said the company is prioritizing investments in programs where emerging evidence supports the greatest potential value,
– Data presentation to include safety, pharmacokinetics (PK), and pharmacodynamics (PD) from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) – NEW HAVEN, Conn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preliminary clinical data from the Phase 1 study of ARV-393 (zaloblideg) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) will be presented at the 2026 American Society of Hematology (ASH®) Annual Meeting, taking place December 12- 15, 2026, in New Orleans, Louisiana.
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $0.48 per share a year ago.
Benchmark ARVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arvinas, Inc. (ARVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.41 | $413.58M | -44.12 | -0.3% | -3.45% | -2% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $277.62 | $7.74B | -23.85 | -100% | — | -34.15% | — | |
| $399.63 | $9.21B | -77.92 | 432.05% | -10.89% | -27.07% | — | |
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — |
Arvinas, Inc. (ARVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arvinas, Inc. (ARVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 3, 2026·SEC
Aug 4, 2026·SEC
Jun 25, 2026·SEC
Get notified when ARVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arvinas, Inc. (ARVN) stock FAQ — growth, dividends, profitability & financials explained
Arvinas, Inc. (ARVN) reported $275.3M in revenue over the trailing twelve months. Revenue was $262.6M in fiscal year 2025. That is 3838% more than the $6.7M of fiscal year 2016.
Arvinas, Inc. (ARVN) revenue fell by 11.8% over the trailing twelve months, compared with the twelve months before.
No. Arvinas, Inc. (ARVN) reported a net loss of $9.5M over the trailing twelve months.
Arvinas, Inc. (ARVN) had a return on equity (ROE) of -2.0% over the trailing twelve months. A negative ROE means the company lost money over the period.
Arvinas, Inc. (ARVN) had negative free cash flow of $159.8M over the trailing twelve months.
